Claims
- 1. Essentially pure human H2-preprorelaxin, which is free of other human proteins.
- 2. Essentially pure human H2-prorelaxin, which is free of other human proteins.
- 3. The essentially pure human H2-prorelaxin as claimed in claim 2, comprising:
- (i) a human H2-relaxin A chain having the sequence: ##STR1## (ii) a human H2-relaxin B chain having the sequence: ##STR2## (iii) a human H2-prorelaxin C chain having the amino acid sequence set forth in FIGS. 2A through 2D as arranged in FIG. 2.
- 4. An essentially pure polypeptide, wherein said polypeptide comprises:
- (i) a human H2-relaxin A chain selected from the group consisting of A(1-24) to A(5-24), wherein amino acids 1-24 have the following sequence: ##STR3## (ii) a human H2-relaxin B chain selected from the group consisting of b(-1-32) to B(4-23), wherein amino acids -1-32 have the following sequence: ##STR4## (iii) a human H2-prorelaxin C chain having the amino acid sequence as set forth in FIGS. 2A through 2D as arranged in FIG. 2, wherein the C chain amino acid sequence is modified at the junction of the B/C and C/A chains to facilitate cleavage at the B/C and C/A junctions and subsequent excision of the C chain.
- 5. The essentially pure polypeptide according to claim 4, wherein the A and B chains of said polypeptide comprise:
- (i) a human H2-relaxin A chain selected from the group consisting of A(1-24) to A(3-24); and
- (ii) a human H2-relaxin B chain selected from the group consisting of B(-1-32) to B(-1-24).
- 6. The essentially pure polypeptide as claimed in claim 4, wherein said B chain has been modified by replacement of the Met residue at B(24) with a member selected from the group consisting of valine, alanine, glycine and serine.
- 7. An essentially pure polypeptide selected from the group consisting of signal, A, B, and C polypeptide chains of human H2-preprorelaxins, which is free of other human proteins.
- 8. The essentially pure polypeptide as claimed in claim 7, wherein said A polypeptide chain is
- (i) a human H2-relaxin A chain selected from the group consisting of A(1-24) to A(5-24), wherein amino acids 1-24 have the following sequence: ##STR5## and, wherein said B polypeptide chain is (ii) a human H2-relaxin B chain selected from the group consisting of B(--32) to B(4-23), wherein amino acids -1-32 have the following sequence; ##STR6## and, wherein said C polypeptide chain is (iii) a human H2-prorelaxin C chain having the amino acid sequence as set forth in FIGS. 2A through 2D as arranged in FIG. 2.
- 9. The essentially pure polypeptide according to claim 8, wherein said A polypeptide chain is
- (i) a human H2-relaxin A chain selected rom the group consisting of A (1-24) to A(3-24); and wherein said B polypeptide chain is
- (ii) a human H2-relaxin B chain selected from the group consisting of B(-1-32) to B(-1-24).
- 10. The essentially pure polypeptide as claimed in claim 9, wherein said B polypeptide chain has been modified by one or more procedures selected from the group consisting of
- (a) formylation of the Trp residue at B(2); and
- (b) replacement of the Met residue at B(24) with a member selected from the group consisting of norleucine, valine, alanine, glycine, serine and homoserine.
Priority Claims (1)
Number |
Date |
Country |
Kind |
PF7247/82 |
Dec 1982 |
AUX |
|
Parent Case Info
This is a divisional of application Ser. No. 071021,855, filed Mar. 4, 1987, now U.S. Pat. No. 5,023,321, which is a divisional of application Ser. No. 06/560,790, filed Dec. 13, 1983, now U.S. Pat. No. 4,758,516.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4758516 |
Hudson et al. |
Jul 1988 |
|
5023321 |
Hudson et al. |
Jun 1991 |
|
Divisions (2)
|
Number |
Date |
Country |
Parent |
21885 |
Mar 1987 |
|
Parent |
560790 |
Dec 1983 |
|